{"analyses":[{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.31","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8879","paramType":"Hazard Ratio (HR)","paramValue":"0.98","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.57","upperLimit":"11.24","value":"6.41"},{"groupId":"OG001","lowerLimit":"4.99","upperLimit":"12.12","value":"7.56"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"167"}],"units":"Participants"}],"description":"Deterioration in GHS/HRQoL (Items 29, 30 of the EORTC QLQ C30) was defined by the following two criteria: 1. The time from randomization to the first time the participants's GHS/HRQoL scale score showed a \\>=10-point decrease from the baseline scale score. A 10-point change was defined as the minimally important difference (MID). 2. The score decrease of \\>= 10-points from baseline was held for at least two consecutive cycles, or an initial score decrease of \\>= 10-points was followed by death or treatment discontinuation within 3 weeks from the last assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo Plus Nab-Paclitaxel"},{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab Plus Nab-Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"The patient-reported outcome (PRO)-evaluable population is defined as patients in the ITT population with a baseline and ≥1 post-baseline PRO assessment.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 58 months","title":"TTD in Global Health Status/Health Related Quality of Life According to EORTC QLQ-C30 v3.0 in Participants With Detectable PD-L1","type":"SECONDARY","unitOfMeasure":"Months"}